Amgen Drugs May Boost Survival During a Nuclear Attack

Amgen Inc.’s Neulasta and Neupogen and a similar blood-boosting drug from Teva Pharmaceutical Industries Ltd. may help people survive after a nuclear attack, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.